SCHEMBL3075207

SCHEMBL3075207

Cc1cccc(O)c1CC#N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.45
ATM Q13315 1/20 0.45
ALDH1A1 P00352 5/20 0.39
MMP3 P08254 1/20 0.36
TSHR P16473 1/20 0.34
ENPP2 Q13822 1/20 0.34
GAA P10253 3/20 0.34
MAPT P10636 3/20 0.34
HSD17B10 Q99714 2/20 0.34
TP53 P04637 1/20 0.34
MAPK1 P28482 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA12 O43570 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
MGAM O43451 2/20 0.33
SI P14410 2/20 0.33
MGAM2 Q2M2H8 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL954804 0.85 TSHR (0.41) ALDH1A1MMP3TSHRENPP2MAPT
SCHEMBL20249844 0.80 ACHE (0.43) ALDH1A1TSHRGAAMAPTMGAM
SCHEMBL31459480 0.80 ACHE (0.43) ALDH1A1TSHRGAAMAPTMGAM
SCHEMBL8763095 0.78 ALDH1A1 (0.39) ALDH1A1TSHRENPP2CA1CA2
SCHEMBL3187578 0.77 ENPP2 (0.43) ALDH1A1MMP3ENPP2MAPTHSD17B10
SCHEMBL29769881 0.76 TRPA1 (0.54) TRPA1ATMALDH1A1GAAMAPT
SCHEMBL9156005 0.76 TRPA1 (0.54) TRPA1ATMALDH1A1GAAMAPT
SCHEMBL11114860 0.76 TAAR1 (0.38) ALDH1A1TSHRMEN1KMT2AKDM4E
SCHEMBL31459423 0.76 TAAR1 (0.38) ALDH1A1TSHRMEN1KMT2AKDM4E
SCHEMBL30755316 0.76 ALDH1A1 (0.43) ALDH1A1TSHRENPP2MAPTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012055-A1 Organic compounds REN, ACE, ACE2 TRPA1 186/4885ATM 4692/4885ALDH1A1 142/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 TRPA1 186/4885ATM 4692/4885ALDH1A1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.